

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/178196 A1

(51) International Patent Classification:

A61K 39/095 (2006.01) C07K 14/22 (2006.01)
A61P 31/04 (2006.01)

(21) International Application Number:

PCT/US2022/016894

(22) International Filing Date:

18 February 2022 (18.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21305211.1 19 February 2021 (19.02.2021) EP
63/172,885 09 April 2021 (09.04.2021) US

(71) Applicant: **SANOFI PASTEUR INC.** [US/US]; IP Dept,
38 Sydney Street, Cambridge, Massachusetts 02140 (US).

(72) Inventors: **ARNAUD-BARBE, Nadège**; c/o Sanofi,
Patent Department, 54 rue La Boétie, 75008 Paris (FR).
BALHARA, Vinod; c/o Sanofi Pasteur Ltd, 1755 Steeles
Avenue, West, Toronto, Ontario M2R 3T4 (CA). **IAN-
TOMASI, Raffaella**; c/o Sanofi, Patent Department, 54 rue
La Boétie, 75008 Paris (FR). **KAZEK-DURET, Marie-
Pierre**; c/o Sanofi, Patent Department, 54 rue La Boétie,
75008 Paris (FR). **MCCLUSKEY, Jacqueline**; c/o Sanofi
Pasteur Inc., IP Dept, 38 Sydney Street, Cambridge, Mass-
achusetts 02140 (US). **QUEMENEUR, Laurence**; c/o
Sanofi, Patent Department, 54 rue La Boétie, 75008 Paris
(FR). **ROKBI, Bachra**; c/o Sanofi, Patent Department, 54
rue La Boétie, 75008 Paris (FR). **SHIVER, John**; c/o Sanofi
Pasteur Inc., IP Dept, 38 Sydney Street, Cambridge, Mass-
achusetts 02140 (US).

(74) Agent: **VELEMA, James H.**; LATHROP GPM LLP, 28
State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MENINGOCOCCAL B RECOMBINANT VACCINE

(57) Abstract: The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.

WO 2022/178196 A1